Related Experiment Video
Updated: Jun 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment
A Casabianca1, M Marchetti, F Zallio
1Infectious and Tropical Diseases Unit, Cardinal Massaja Hospital, Corso Dante 202, 14100 Asti, Italy. casabianca@asl.at.it
Abstract:
Both the presentation and clinical course of visceral leishmaniasis (VL) may be atypical in immunosuppressed subjects, often resulting in delayed diagnosis and treatment. We describe a case of VL characterized by negative serologic testing, a relapsing course, and a fatal outcome 2 years after the patient had been successfully treated for non-Hodgkin's lymphoma with rituximab. Diagnosis of VL may be further delayed or even missed in patients treated with drugs that interfere with specific antibody production unless specific diagnostic methods, such as bone marrow examination and parasite DNA amplification/detection, are routinely employed.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents
Rocky Mountain Spotted Fever
Rabies
Respiratory Syncytial Virus Disease
American Trypanosomiasis